122 related articles for article (PubMed ID: 37327205)
1. Genetic Profiling of African American Patients With Prostatic Adenocarcinoma Metastatic to the Lymph Nodes: A Pilot Study.
Bidot S; Yin J; Zhou P; Zhang L; Deeb KK; Smith G; Hill CE; Xiu J; Bilen MA; Case KB; Tinsley M; Carthon B; Harik LR
Arch Pathol Lab Med; 2024 Mar; 148(3):310-317. PubMed ID: 37327205
[TBL] [Abstract][Full Text] [Related]
2. G3BP1 inhibits Cul3
Mukhopadhyay C; Yang C; Xu L; Liu D; Wang Y; Huang D; Deonarine LD; Cyrta J; Davicioni E; Sboner A; Robinson BD; Chinnaiyan AM; Rubin MA; Barbieri CE; Zhou P
Nat Commun; 2021 Nov; 12(1):6662. PubMed ID: 34795264
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.
Geng C; Rajapakshe K; Shah SS; Shou J; Eedunuri VK; Foley C; Fiskus W; Rajendran M; Chew SA; Zimmermann M; Bond R; He B; Coarfa C; Mitsiades N
Cancer Res; 2014 Oct; 74(19):5631-43. PubMed ID: 25274033
[TBL] [Abstract][Full Text] [Related]
4. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
5. Clinical and genomic features of SPOP-mutant prostate cancer.
Nakazawa M; Fang M; H Marshall C; Lotan TL; Isaacsson Velho P; Antonarakis ES
Prostate; 2022 Feb; 82(2):260-268. PubMed ID: 34783071
[TBL] [Abstract][Full Text] [Related]
6. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
7. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer.
Groner AC; Cato L; de Tribolet-Hardy J; Bernasocchi T; Janouskova H; Melchers D; Houtman R; Cato ACB; Tschopp P; Gu L; Corsinotti A; Zhong Q; Fankhauser C; Fritz C; Poyet C; Wagner U; Guo T; Aebersold R; Garraway LA; Wild PJ; Theurillat JP; Brown M
Cancer Cell; 2016 Jun; 29(6):846-858. PubMed ID: 27238081
[TBL] [Abstract][Full Text] [Related]
8. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
[TBL] [Abstract][Full Text] [Related]
9. Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis.
Ge Y; Jin J; Chen G; Li J; Ye M; Jin X
Cell Commun Signal; 2023 Oct; 21(1):303. PubMed ID: 37904149
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer.
Theurillat JP; Udeshi ND; Errington WJ; Svinkina T; Baca SC; Pop M; Wild PJ; Blattner M; Groner AC; Rubin MA; Moch H; Prive GG; Carr SA; Garraway LA
Science; 2014 Oct; 346(6205):85-89. PubMed ID: 25278611
[TBL] [Abstract][Full Text] [Related]
11. Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer.
Bernasocchi T; El Tekle G; Bolis M; Mutti A; Vallerga A; Brandt LP; Spriano F; Svinkina T; Zoma M; Ceserani V; Rinaldi A; Janouskova H; Bossi D; Cavalli M; Mosole S; Geiger R; Dong Z; Yang CG; Albino D; Rinaldi A; Schraml P; Linder S; Carbone GM; Alimonti A; Bertoni F; Moch H; Carr SA; Zwart W; Kruithof-de Julio M; Rubin MA; Udeshi ND; Theurillat JP
Nat Commun; 2021 Feb; 12(1):734. PubMed ID: 33531470
[TBL] [Abstract][Full Text] [Related]
12. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants.
An J; Wang C; Deng Y; Yu L; Huang H
Cell Rep; 2014 Feb; 6(4):657-69. PubMed ID: 24508459
[TBL] [Abstract][Full Text] [Related]
13. Mutated SPOP E3 Ligase Promotes 17βHSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression.
Shi L; Yan Y; He Y; Yan B; Pan Y; Orme JJ; Zhang J; Xu W; Pang J; Huang H
Cancer Res; 2021 Jul; 81(13):3593-3606. PubMed ID: 33762355
[TBL] [Abstract][Full Text] [Related]
14. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Watanabe R; Maekawa M; Hieda M; Taguchi T; Miura N; Kikugawa T; Saika T; Higashiyama S
Mol Biol Cell; 2020 Mar; 31(6):478-490. PubMed ID: 31967940
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.
Geng C; He B; Xu L; Barbieri CE; Eedunuri VK; Chew SA; Zimmermann M; Bond R; Shou J; Li C; Blattner M; Lonard DM; Demichelis F; Coarfa C; Rubin MA; Zhou P; O'Malley BW; Mitsiades N
Proc Natl Acad Sci U S A; 2013 Apr; 110(17):6997-7002. PubMed ID: 23559371
[TBL] [Abstract][Full Text] [Related]
16. TRIM28 protects TRIM24 from SPOP-mediated degradation and promotes prostate cancer progression.
Fong KW; Zhao JC; Song B; Zheng B; Yu J
Nat Commun; 2018 Nov; 9(1):5007. PubMed ID: 30479348
[TBL] [Abstract][Full Text] [Related]
17. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract][Full Text] [Related]
18. SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.
Blattner M; Liu D; Robinson BD; Huang D; Poliakov A; Gao D; Nataraj S; Deonarine LD; Augello MA; Sailer V; Ponnala L; Ittmann M; Chinnaiyan AM; Sboner A; Chen Y; Rubin MA; Barbieri CE
Cancer Cell; 2017 Mar; 31(3):436-451. PubMed ID: 28292441
[TBL] [Abstract][Full Text] [Related]
19. Integrative comparison of the genomic and transcriptomic landscape between prostate cancer patients of predominantly African or European genetic ancestry.
Yuan J; Kensler KH; Hu Z; Zhang Y; Zhang T; Jiang J; Xu M; Pan Y; Long M; Montone KT; Tanyi JL; Fan Y; Zhang R; Hu X; Rebbeck TR; Zhang L
PLoS Genet; 2020 Feb; 16(2):e1008641. PubMed ID: 32059012
[TBL] [Abstract][Full Text] [Related]
20. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
